Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Lancet Neurology

• Publication date

  2017-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1474-4422(17)30005-4PMID 28216232
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trigeminal neuralgia.

  2022cited by this paper
• Botulinum Toxin for the Treatment of Neuropathic Pain

  2017cited by this paper
• Botulinum Toxin Treatment of Neuropathic Pain

  2016cited by this paper
• Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia

  2016cited by this paper
• Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting

  2015cited by this paper
• Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP)

  2015cited by this paper
• Sidedness of Carbamazepine Accessibility to Voltage-Gated Sodium Channels

  2014cited by this paper
• Trigeminal neuralgia.

  2014cited by this paper
• Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain

  2014cited by this paper
• Recent progress in sodium channel modulators for pain.

  2014cited by this paper
• Carbamazepine for chronic neuropathic pain and fibromyalgia in adults.

  2014cited by this paper
• Non-antiepileptic drugs for trigeminal neuralgia.

  2013cited by this paper
• Non-antiepileptic drugs for trigeminal neuralgia.

  2013cited by this paper
• Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia

  2013influential reference
• The International Classification of Headache Disorders, 3rd edition (beta version)

  2013cited by this paper
• Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.

  2013cited by this paper
• The NaV1.7 sodium channel: from molecule to man

  2012cited by this paper
• Development of and psychometric testing for the Brief Pain Inventory-Facial in patients with facial pain syndromes.

  2010cited by this paper
• Sodium channels in normal and pathological pain.

  2010cited by this paper
• Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls

  2009cited by this paper
• Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.

  2008cited by this paper
• AAN‐EFNS guidelines on trigeminal neuralgia management

  2008cited by this paper
• The International Classification of Headache Disorders

  2008cited by this paper
• Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam

  2007cited by this paper
• An SCN9A channelopathy causes congenital inability to experience pain

  2006cited by this paper
• Cognitive and memory effects of the new antiepileptic drugs.

  2006cited by this paper
• The International Classification of Headache Disorders: 2nd edition.

  2004cited by this paper
• Antiepileptic drugs and memory.

  2004cited by this paper
• Pathophysiology of trigeminal neuralgia: new evidence from a trigeminal ganglion intraoperative microneurographic recording. Case report.

  2004cited by this paper
• The International Classification of Headache Disorders: 2nd edition

  2003cited by this paper
• Guidance for Industry E 10 Choice of Control Group and Related Issues in Clinical Trials

  2001cited by this paper
• Trigeminal neuralgia: The role of self-sustaining discharge in the trigeminal ganglion

  1994cited by this paper
• Antiepileptic Drugs and Memory

  1992cited by this paper

• Innovative strategies for diabetic peripheral neuropathy: From clinical management to emerging bioengineering solutions.

  2026cites this paper
• Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review.

  2026cites this paper
• Anticonvulsant Therapy in Trigeminal Neuralgia: A Class-Oriented Systematic Review.

  2026cites this paper
• Sodium Channel Inhibitors in Clinical Development for Pain Management: A Focused Review

  2025cites this paper
• Centrally Acting Skeletal Muscle Relaxants Sharing Molecular Targets with Drugs for Neuropathic Pain Management

  2025cites this paper
• Beyond single targets: leveraging degeneracy in sodium channels for osteoarthritis analgesia

  2025cites this paper
• Trpv1-dependent Cacna1b gene inactivation reveals cell-specific functions of CaV2.2 channels in vivo

  2025cites this paper
• Voltage-gated sodium channels in excitable cells as drug targets

  2025influential citation
• Preclinical Animal Models to Investigate the Role of Nav1.7 Ion Channels in Pain

  2025influential citation
• Efficacy of Sodium Channel-Selective Analgesics in Postoperative, Neuralgia, and Neuropathy-Related Pain Management: A Systematic Review and Literature Review

  2025cites this paper
• Mechanism-based nonopioid analgesic targets

  2025cites this paper
• Diabetic neuropathy: cutting-edge research and future directions

  2025cites this paper
• Electrophysiology in neuropathic pain: a bibliometric analysis and literature review

  2025cites this paper
• Six at Sixty. ‘No gain, no pain’: medical genetics taking Nav1.7 from target to pharmacy

  2025cites this paper
• Towards development of Nav1.7 channel modulators for pain treatment: A comparison of mexiletine effect in two cell models by automated patch clamp.

  2025cites this paper
• Five-year prospective outcomes of medical management and microvascular decompression in trigeminal neuralgia

  2025cites this paper
• The role and mechanisms of matrix metalloproteinase-9 in peripheral neuropathic pain

  2025cites this paper
• Transcranial Magnetic Stimulation to Treat Neuropathic Pain: A Bibliometric Analysis

  2024cites this paper
• In-Hospital Management of Acute Trigeminal Neuralgia Pain Crises

  2024cites this paper
• Novel non-opioid analgesics in pain management.

  2024cites this paper
• Development and characterization of pyridyl carboxamides as potent and highly selective Nav1.8 inhibitors.

  2024cites this paper
• Discovery of E0199: A novel compound targeting both peripheral NaV and KV7 channels to alleviate neuropathic pain

  2024cites this paper
• Discordance between preclinical and clinical testing of NaV1.7-selective inhibitors for pain

  2024cites this paper
• The PATCH trial: 5% lidocaine‐medicated plaster for trigeminal neuralgia—Results of a multicentric, enriched enrollment, randomized withdrawal, double‐blind, vehicle‐controlled, parallel‐group study

  2024cites this paper
• An overview of the safety and efficacy of LX-9211 in treating neuropathic pain conditions

  2024cites this paper
• Nanomedicine and voltage-gated sodium channel blockers in pain management: a game changer or a lost cause?

  2024cites this paper
• PHARMACOTHERAPY AND NONINVASIVE NEUROSTIMULATION FOR NEUROPATHIC PAIN.

  2024cites this paper
• An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia

  2024cites this paper
• The pathophysiology of trigeminal neuralgia: a molecular review.

  2023cites this paper
• Compression Degree of Trigeminal Nerve and Type of Conflicting Vessels Determine Short- and Long-Term Complete Pain Relief in Adult Patients with Primary Trigeminal Neuralgia After Microvascular Decompression: A Three-Year Retrospective Study of 200 Adult Patients with Primary Trigeminal Neuralgia

  2023cites this paper
• Lessons learned in translating pain knowledge into practice

  2023cites this paper
• Neuropathic pain; what we know and what we should do about it

  2023cites this paper
• An Overview of Ion Channels Therapeutics in the Treatment of Pain

  2023cites this paper
• Advances and challenges in neuropathic pain: a narrative review and future directions.

  2023cites this paper
• Efficacy and safety of vixotrigine in idiopathic or diabetes-associated painful small fibre neuropathy (CONVEY): a phase 2 placebo-controlled enriched-enrolment randomised withdrawal study

  2023cites this paper
• Targeted Therapy for Orofacial Pain: A Novel Perspective for Precision Medicine

  2023cites this paper
• PACAP inhibition alleviates neuropathic pain by modulating Nav1.7 through the MAPK/ERK signaling pathway in a rat model of chronic constriction injury.

  2023cites this paper
• Diagnosis and Management of Neuropathic Pain in Spine Diseases

  2023cites this paper
• Trigeminal Neuralgia: Diagnosis and Treatment.

  2023cites this paper
• Identification and targeting of a unique NaV1.7 domain driving chronic pain

  2023cites this paper
• Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study.

  2022cites this paper
• Recent advances for using human induced-pluripotent stem cells as pain-in-a-dish models of neuropathic pain.

  2022cites this paper
• Evaluation of the Effect of Uridine Diphosphate-Glucuronosyltransferases (UGT) Inhibition by Valproic Acid on Vixotrigine Pharmacokinetics in Healthy Volunteers

  2022cites this paper
• Inhibition of NaV1.7: the possibility of ideal analgesics.

  2022cites this paper
• Structural basis for NaV1.7 inhibition by pore blockers.

  2022cites this paper
• Identification and targeting of a unique NaV1.7 domain driving chronic pain

  2022cites this paper
• Neuroinflammation Involved in Diabetes-Related Pain and Itch

  2022cites this paper
• Novel ways of approaching the pharmacologic treatment of trigeminal neuralgia

  2022cites this paper
• Analgesia linked to Nav1.7 loss of function requires µ-and δ-opioid receptors [version 1; peer review: 2 approved]

  2022cites this paper
• A Review of Medical and Surgical Options for the Treatment of Facial Pain.

  2022cites this paper
• Presente y futuras perspectivas en el abordaje farmacológico del dolor neuropático

  2022cites this paper
• Abordaje farmacológico del dolor neuropático: pasado, presente y futuro

  2022cites this paper
• Study Design Characteristics and Endpoints for Enriched Enrollment Randomized Withdrawal Trials for Chronic Pain Patients: A Systematic Review

  2022influential citation
• Narrow ovale foramina may be involved in the development of primary trigeminal neuralgia

  2022cites this paper
• Normalization of Neuroinflammation: A New Strategy for Treatment of Persistent Pain and Memory/Emotional Deficits in Chronic Pain

  2022cites this paper
• The voltage-gated sodium channel NaV1.7 underlies endometriosis-associated chronic pelvic pain

  2022influential citation
• Why are sodium channel modulators not yet pharmacotherapeutic trailblazers for neuropathic pain?

  2021cites this paper
• The PATCH trial: efficacy and safety of 5% lidocaine-medicated plaster for the treatment of patients with trigeminal neuralgia: a study protocol for a multicentric, double-blind, enriched enrolment randomised withdrawal, vehicle-controlled study

  2021cites this paper
• Population Pharmacokinetics of Vixotrigine in Healthy Volunteers and Subjects with Trigeminal Neuralgia, Painful Lumbosacral Radiculopathy and Erythromelalgia

  2021cites this paper
• Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets

  2021cites this paper
• Real‐world effectiveness and tolerability of carbamazepine and oxcarbazepine in 354 patients with trigeminal neuralgia

  2021cites this paper
• Characterization of Vixotrigine, a Broad-Spectrum Voltage-Gated Sodium Channel Blocker.

  2021cites this paper
• Future Research in Pain

  2021cites this paper
• Cognitive Behavioral Therapy for Patients with Trigeminal Neuralgia: A Feasibility Study.

  2021cites this paper
• Inhibition of the Nav1.7 Channel in the Trigeminal Ganglion Relieves Pulpitis Inflammatory Pain

  2021cites this paper
• Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents

  2021cites this paper
• Advances in the treatment of neuropathic pain

  2021cites this paper
• Exploring Experimental Autoimmune Encephalomyelitis as an Animal Model to Study Trigeminal Dysfunction in Multiple Sclerosis

  2021cites this paper
• Efficacy of medications in adult patients with trigeminal neuralgia compared to placebo intervention: a systematic review with meta-analyses

  2021influential citation
• Tetrodotoxin: A New Strategy to Treat Visceral Pain?

  2021cites this paper
• Studying human nociceptors: from fundamentals to clinic

  2021influential citation
• Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis

  2021cites this paper
• Clinical Effect of Partial Sensory Root Rhizotomy on Recurrence of Multiple Sclerosing Trigeminal Neuralgia After Percutaneous Balloon Compression

  2021cites this paper
• The role of peripheral nerve signaling in endometriosis

  2021cites this paper
• Aspetti clinici e terapeutici della nevralgia dei nervi trigemino e glossofaringeo

  2021cites this paper
• TRIGEMINAL NEURALGIA AND ITS RECENT ADVANCES

  2020cites this paper
• Trigeminal Neuralgia: Basic and Clinical Aspects

  2020cites this paper
• [EXPRESS] Trigeminal Neuralgia: an overview from pathophysiology to pharmacological treatments.

  2020cites this paper
• Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers

  2020cites this paper
• Treatment Outcomes in Trigeminal Neuralgia–A Systematic Review of Domains, Dimensions and Measures

  2020cites this paper
• Biomarkers in temporomandibular disorder and trigeminal neuralgia: A conceptual framework for understanding chronic pain

  2020cites this paper
• Voltage-gated sodium channel blockers: New perspectives in the treatment of neuropathic pain.

  2020cites this paper
• Spider venom-derived peptide induces hyperalgesia in Nav1.7 knockout mice by activating Nav1.9 channels

  2020cites this paper
• Mechanism underlying cranial nerve rhizopathy.

  2020cites this paper
• Resilience to Stress and Resilience to Pain: Lessons from Molecular Neurobiology and Genetics.

  2020cites this paper
• Evaluation of the Potential Pharmacokinetic Interactions Between Vixotrigine and an Oral Contraceptive

  2020cites this paper
• Neuropathic pain: From mechanisms to treatment.

  2020cites this paper
• Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia

  2020cites this paper
• Diabetic Peripheral Neuropathy: Diagnosis and Treatment.

  2020cites this paper
• Rational Drug Design for Pain Medicine: A New Nav1.7 Inhibitor.

  2020cites this paper
• Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia.

  2020cites this paper
• K+ Channels in Primary Afferents and Their Role in Nerve Injury-Induced Pain

  2020cites this paper
• Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia.

  2020cites this paper
• Trigeminusneuralgie

  2020cites this paper
• [Trigeminal neuralgia : Modern diagnostic workup and treatment].

  2020cites this paper
• Spinal cord stimulation for chronic intractable trunk or limb pain: study protocol for a Chinese multicenter randomized withdrawal trial (CITRIP study)

  2020cites this paper
• Controlling the “Opioid Epidemic”: A Novel Chemical Entity (NCE) to Reduce or Supplant Opiate Use for Chronic Pain

  2020cites this paper
• Status of peripheral sodium channel blockers for non-addictive pain treatment

  2020cites this paper
• Fifteen years of NaV1.7 channels as an analgesic target: Why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy?

  2020cites this paper
• Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers

  2020cites this paper